VolitionRx Limited (VNRX) is a Henderson, Nevada-based epigenetics company developing low-cost blood tests built on its Nu.Q platform, aimed at detecting and monitoring cancers and NETosis-related conditions such as sepsis, alongside a veterinary cancer franchise. Shares were quoted at $0.1801 on Wednesday, a decline of 4.56% from the previous session's close of $0.1887. The direction is unambiguously lower, but no single verified news event on the day explains the drop: the company's third-quarter results were released on November 12, and the current price action represents the continued fading of the sharp rally those results produced.
The dominant force behind Wednesday's decline is the unwinding of the earnings-driven move from November 13, when VNRX jumped 24.7% to $0.2300 on roughly 57 million shares — many times its normal turnover — after third-quarter revenue of $1.61 million crushed a consensus near $706,000 and the quarterly net loss narrowed to about $3.8 million from $5.4 million a year earlier. That surge has been steadily reversed: shares fell 13.1% on November 16 and another 5.6% on November 17 before Wednesday's slide, leaving the stock roughly 22% below its post-earnings closing level. This pattern is consistent with short-term traders taking profits on a nano-cap spike rather than with a fresh deterioration in the business.
Underneath the earnings reaction sits a structural headwind that has weighed on the equity all year. Shares outstanding of roughly 36 million are more than double the year-earlier figure, and the company carries a market value of only about $6.6 million after a 52-week decline of roughly 97%. Management has made debt reduction a priority — retiring a $7.5 million convertible note in September and prepaying $500,000 against a $2.4 million note in October, leaving about $0.7 million outstanding — while the lender agreed to pause conversion rights until January 2027 unless the closing price reaches $0.275. Those steps reduce future dilution risk, but the very low share price keeps the conversion and capital-raising question in front of investors.
Wednesday's backdrop offered no sector-wide excuse. The S&P 500 proxy slipped about 0.5% and the iShares Biotechnology ETF (IBB) eased a similar amount, while the SPDR S&P Biotech ETF (XBI) was marginally higher, so small-cap biotech was essentially flat. Turnover in VNRX reached only about 1.1 million shares by late morning against a 20-day average near 4 million, confirming that the selling was thin rather than forceful. The stock traded a wide intraday band of roughly $0.170 to $0.185 and remains about 20% below its 50-day moving average near $0.226 and far beneath its 200-day line.
The score runs from 0, meaning no meaningful news and a routine price move, to 100, meaning transformative news and an extreme, rare move. This event lands at 12 out of 100. The verified news backdrop is thin for the session itself: a quarterly beat and a debt-reduction program were disclosed days earlier and are modest in scale relative to a company with roughly $6.6 million in market value and no 2026 guidance.
The price behavior was equally unremarkable by this stock's standards. The 4.56% decline was only about 0.8 times the typical daily move of roughly 5.8%, and 28 of the prior 60 sessions produced an equal or larger swing. With neither a strong catalyst nor an anomalous move, the two factors combine into a low score.
The next scheduled financial update is not expected until the first quarter of 2027, leaving investors to trade on operational news flow in the interim. The most immediate items are the planned French reimbursement submission for the Nu.Q Lung Cancer test, publication of the peer-reviewed feline lymphoma study that would satisfy a condition for a $5 million milestone payment, and progress in licensing discussions with major diagnostics and liquid biopsy companies, including the Missionpharma letter of intent covering point-of-care sepsis triage. Four analysts currently carry a Buy consensus, though their views span an unusually wide range. Risks include continued cash burn, the possibility of further equity issuance, reliance on partner timelines, and the persistent sub-$1 price that constrains institutional participation.
Tickeron operates a curated Trending AI Robots page that surfaces only the strongest performing automated strategies under present market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured list changes as conditions evolve. Investors looking for systematic approaches to volatile names may find it a useful starting point for further research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for VNRX moved into oversold territory on November 18, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VNRX's RSI Oscillator exited the oversold zone, 27 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +5.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNRX advanced for three days, in 146 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In 90 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
VNRX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VNRX broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VNRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.183) is normal, around the industry mean (4.142). P/E Ratio (-0.051) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.767) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a development stage life sciences company
Industry MedicalNursingServices